Literature DB >> 19115169

Sedation and pain management in acute neurological disease.

Marek A Mirski1, John J Lewin.   

Abstract

The optimum provision of pharmacological sedation of the critically ill neurological patient requires defining the underlying etiology of agitation or need for sedation to determine the optimal agent: pain management, anxiolysis, or treatment of delirium. An appropriate regimen can then be decided upon based on the profiles of action of the several common classes of sedative agents. Methods to both evaluate the efficacy of sedation as well as titration to a predefined clinical goal are important tools toward safe administration of drugs that often have serious adverse effects. Recognition of an individualized approach is also necessary as patients will vary considerably with respect to the kinetics and pharmacodynamics of sedative therapy. The drug classes often selected for sedation in an intensive care unit will be reviewed as well as the metrics by which physicians can achieve their objectives in a safe manner.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19115169     DOI: 10.1055/s-0028-1105970

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  3 in total

1.  Dosing evaluation of continuous intravenous fentanyl infusions in overweight children: a pilot study.

Authors:  Emily C Gish; Donald Harrison; Andrew K Gormley; Peter N Johnson
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

2.  ICU sedation with dexmedetomidine after severe traumatic brain injury.

Authors:  Stephen S Humble; Laura D Wilson; Taylor C Leath; Matthew D Marshall; Daniel Z Sun; Pratik P Pandharipande; Mayur B Patel
Journal:  Brain Inj       Date:  2016-07-26       Impact factor: 2.311

Review 3.  An overview of management of intracranial hypertension in the intensive care unit.

Authors:  Theodoros Schizodimos; Vasiliki Soulountsi; Christina Iasonidou; Nikos Kapravelos
Journal:  J Anesth       Date:  2020-05-21       Impact factor: 2.931

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.